Ventyx Biosciences Inc (VTYX)
4.435
-0.24
(-5.13%)
USD |
NASDAQ |
May 23, 16:00
4.435
0.00 (0.00%)
After-Hours: 17:14
Ventyx Biosciences Cash from Financing (Quarterly): 96.18M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 96.18M |
| December 31, 2023 | 0.585M |
| September 30, 2023 | 1.625M |
| June 30, 2023 | 2.473M |
| March 31, 2023 | 48.65M |
| December 31, 2022 | -10.36M |
| September 30, 2022 | 177.79M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.249M |
| March 31, 2022 | 0.086M |
| December 31, 2021 | 159.58M |
| September 30, 2021 | 50.38M |
| June 30, 2021 | 56.72M |
| March 31, 2021 | 56.86M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-10.36M
Minimum
Dec 2022
177.79M
Maximum
Sep 2022
49.30M
Average
48.65M
Median
Mar 2023
Cash from Financing (Quarterly) Benchmarks
| Anavex Life Sciences Corp | 7.277M |
| CERo Therapeutics Holdings Inc | -- |
| Avinger Inc | 6.633M |
| Checkpoint Therapeutics Inc | 12.79M |
| RAPT Therapeutics Inc | 9.036M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -47.62M |
| Cash from Investing (Quarterly) | 41.76M |
| Free Cash Flow | -183.86M |
| Free Cash Flow Per Share (Quarterly) | -0.7731 |
| Free Cash Flow Yield | -69.57% |